Blog

FSD Pharma Breaks All-Time Monthly Stock Volume Trading Record

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

CSE: HUGE

TORONTO, July 5, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE), is pleased to report that in the one month period of trading between May 29, 2018 and June 28, 2018, the company traded exactly 869,232,894 Class B subordinate voting shares on the Canadian Securities Exchange (“CSE”). Continue Reading

FSD Pharma Inc. announces $55 million dollar indoor cannabis grow partnership expansion at its Cobourg facility

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

CSE: HUGE

TORONTOJuly 3, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE) is pleased to provide an update on the progress of the joint venture between its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma) and Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly”). Continue Reading

FSD Pharma Breaks All-Time Weekly Stock Volume Trading Record

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

CSE: HUGE

TORONTOJune 25, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE), is pleased to report that in the last 5 consecutive days of trading, the company traded exactly 269,961,050 Class B subordinate voting shares on the Canadian Securities Exchange (“CSE”). Continue Reading

FSD Pharma Inc. Announces Appointment of Chief Commercial Officer

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

CSE: HUGE

TORONTOJune 21, 2018 /CNW/ – Thomas Fairfull, President and Chief Executive Officer of FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE), is pleased to announce the appointment of Mr. Michael Ash as the Chief Commercial Officer of FV Pharma Inc. (“FV Pharma”), a wholly-owned subsidiary of the Company. Continue Reading

FSD Pharma Inc. Announces a Partnership Agreement with Cannara Biotech Inc. to Allow for Indoor Grow Space to Increase to a Combined 1,245,000 Square Feet

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

TORONTOJune 19, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or “The Company”) (CSE:HUGE), announced the signing of a partnership agreement between FV Pharma Inc. (“FV Pharma”), a wholly-owned subsidiary of the Company, and Cannara Biotech Inc. (“Cannara”) effective May 31, 2018. Continue Reading

FSD Pharma Inc. Added to the CSE 25 Composite Index

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

CSE: HUGE

TORONTOJune 18, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE) has been added to the CSE 25 Composite Index, effective after the close on Friday, June 15, 2018. Continue Reading

FSD Pharma Inc. Announces Appointment of New Director

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

CSE: HUGE

TORONTOJune 14, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company“) (CSE: HUGE), is pleased to announce the appointment of Mr. Anthony Durkacz to its Board of Directors, effective immediately. Continue Reading

FSD Pharma breaks all-time weekly volume trading record

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

CSE: HUGE

TORONTOJune 7, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE), is pleased to report that in the first 5 consecutive days of trading, the company traded exactly 259,230,820 Class B subordinate voting shares on the Canadian Securities Exchange (“CSE”). Continue Reading